Grass pollen-specific immunoglobulin E (IgE) (sIgE)

Grass pollen-specific immunoglobulin E (IgE) antibodies are specialized glycoproteins produced by the immune system in individuals sensitized to allergens from various grass species, such as Phleum pratense (Timothy grass) [1]. These antibodies are the primary mediators of Type I hypersensitivity reactions, which manifest clinically as allergic rhinitis, conjunctivitis, and allergic asthma [1]. Upon initial exposure to grass pollen, B cells undergo class-switch recombination to produce IgE, which then binds to high-affinity FcεRI receptors on the surface of mast cells and basophils [1, 4]. Subsequent exposure to the same grass allergens causes cross-linking of the IgE-FcεRI complexes, triggering the degranulation of these cells and the release of potent inflammatory mediators like histamine and leukotrienes [1]. In the context of drug development and clinical management, these antibodies are targeted by monoclonal therapies like omalizumab, which sequesters circulating IgE to prevent receptor binding [2]. Additionally, allergen-specific immunotherapy (AIT) utilizes grass pollen extracts to desensitize the immune system, aiming to reduce the levels of these specific IgE antibodies while increasing protective IgG4 levels [3]. Monitoring the concentration of grass pollen-specific IgE in the serum is a standard diagnostic procedure for identifying the specific triggers of a patient's allergic symptoms [4].

Other names

Grass pollen-specific IgEAllergen-specific IgEPhl p-specific IgELol p-specific IgETimothy grass-specific IgEGrass pollen-specific antibody

Omalizumab binds to the Cε3 domain of circulating IgE, preventing its binding to FcεRI receptors on effector cells [2]. Allergen immunotherapy (AIT) induces immune tolerance by promoting T-regulatory cells and IgG4 blocking antibodies, which compete with IgE for allergen binding and eventually lead to a decrease in allergen-specific IgE levels [3].